

Primer izvida testa Stockholm3, ki pokaže nizko tveganje za raka prostate

Stockholm³

TEST RESULTS

PATIENT DATA

Name:
Patient Id:
Birth Date:

CLINICAL DATA

Family history: No
5ARI: Yes
Previous biopsy: Yes

SAMPLE DATA

Sample Id: PA00018002
Test Date: 2/21/2025
Answer Date: 3/11/2025

STOCKHOLM3 RESULTS AND RECOMMENDATION



COMMENT:

Normal risk of prostate cancer. Re-testing is recommended in 2 years.

PSA 2.8 ng/ml

REPORTING DOCTOR

Per Venge,
licenced physician

Stockholm3 combines protein markers (tPSA, fPSA, KLK2, PSP94, GDF15), genetic markers and clinical data to estimate the risk for clinically significant prostate cancer (defined as ISUP ≥ 2). Stockholm3 is based on the STHLM3 clinical study, conducted by the Karolinska Institute in Sweden, and published in European Urology 2017 and The Lancet Oncology 2015. Stockholm3 was validated for men aged 45-74 years and shall not be used for men who already are diagnosed for prostate cancer. The laboratory has used RSE-A/B, CE-marked medical devices delivered by A3P Biomedical AB (organizational number 559252-9100) to compile this test report. A3P Lab AB, Vallongatan 1, 752 28 Uppsala, Sweden. Organizational number: 559163-0255. Phone: +46 20101110. Email: customersupport@a3p.com.

A³P